Stromedix is a technology company.
Stromedix has raised $26.0M across 2 funding rounds.
Stromedix has raised $26.0M in total across 2 funding rounds.
Stromedix has raised $26.0M in total across 2 funding rounds.
Stromedix's investors include Atlas Venture.
Stromedix was a clinical-stage biotechnology company focused on developing innovative therapies for fibrosis and organ failure, targeting chronic conditions like scleroderma and acute organ malfunctions.[1][2][4] It built drug candidates such as BG-00011 (targeting αvβ6 for atrophy, discontinued), STX-200 (targeting CRAF for systemic scleroderma, pending), and others for fibrosis, serving patients with fibrotic diseases and collaborating with institutions like the University of California, San Francisco.[1][2] The company addressed unmet needs in treating long-term medical conditions by leveraging specialized knowledge to expand into cancer and organ failure therapies, raising funding from investors including Biogen Idec, Red Abbey Venture Partners, Frazier Healthcare Partners, Atlas Venture, and New Leaf Venture Partners before its acquisition.[2]
Founded in 2006 in Cambridge, Massachusetts, Stromedix emerged as a biotech startup amid growing interest in fibrosis treatments.[2][4] Key details on founders are not specified in available records, but the company quickly gained traction through venture backing from prominent life sciences investors like Biogen Idec and Atlas Venture.[2] A pivotal moment came with its acquisition by Biogen Idec in February 2012, which integrated its pipeline into a larger platform for fibrotic disease innovation.[3]
Stromedix rode the early-2010s wave of fibrosis and regenerative medicine innovation, a trend driven by advances in integrin biology and biologics for unmet needs in idiopathic pulmonary fibrosis and systemic sclerosis.[1][4] Timing was ideal post-2000s genomics breakthroughs, enabling targeted therapies amid rising organ failure prevalence from aging populations and chronic diseases. Market forces like Biogen's expansion into rare diseases favored it, influencing the ecosystem by contributing pipeline assets to Big Pharma and validating VC models in early-stage biotech.[2][3]
Post-2012 acquisition, Stromedix's assets likely advanced within Biogen's portfolio, potentially evolving its fibrosis candidates toward later-stage trials or commercialization amid ongoing biotech consolidation.[3] Trends like AI-driven drug discovery and precision medicine could amplify legacy impacts, with integrin inhibitors shaping next-gen anti-fibrotic therapies. Its story underscores how nimble biotechs fuel larger players, tying back to its core mission of transforming organ failure treatment.
Stromedix has raised $26.0M across 2 funding rounds. Most recently, it raised $25.0M Series B in April 2008.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2008 | $25.0M Series B | Atlas Venture | |
| Mar 1, 2007 | $1.0M Series A | Atlas Venture |